ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2013
Role of immunosuppressive therapy for the treatment of multiple sclerosis.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- [Effectiveness and tolerance of azathioprine as first-line treatment for multiple sclerosis: a case study from Morocco].The Pan African medical journal · 2024Article
- A Simple Computational Approach to Identify Potential Drugs for Multiple Sclerosis and Cognitive Disorders from Expert Curated Resources.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Influence of immunomodulatory drugs on the gut microbiota.Translational research : the journal of laboratory and clinical medicine · 2021Review
- Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches.Biomarker insights · 2021Review
- Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Review
- Merits and culprits of immunotherapies for neurological diseases in times of COVID-19.EBioMedicine · 2020Review
- Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis.PloS one · 2020Article
- Mesenchymal Stem Cells Enhance Pulmonary Antimicrobial Immunity and Prevent Following Bacterial Infection.Stem cells international · 2020Article
- Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.Therapeutic advances in neurological disorders · 2019Review
- Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.Journal of neurology · 2018Article
- Review
- Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.Therapeutic advances in neurological disorders · 2017Review
- From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.Current neuropharmacology · 2017Review
- [Cell depletion and myoablation for neuroimmunological diseases].Der Nervenarzt · 2016Review
- The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.Current neurology and neuroscience reports · 2016Review
- The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.PloS one · 2016Article
- Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination.Nature neuroscience · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppressives have been used in multiple sclerosis (MS) since 1966. Today, we have many treatments for the relapsing forms of the disease, including 8 US Food and Drug Administration-approved therapies, with more soon to be introduced. Given the current treatment landscape what place do immunosuppressants have in combating MS? Trial work and our experience suggest that immunosuppressives still have an important role in treating MS. Cyclophosphamide finds use in treating patients with severe, inflammatory relapsing remitting MS or those suffering from a fulminant attack. We tend to employ mycophenolate mofetil as an add-on to injectable therapy for patients experiencing breakthrough activity. Some progressive (primary progressive multiple sclerosis or secondary progressive multiple sclerosis) patients may stabilize after treatment with either cyclophosphamide or mycophenolate. We rarely employ mitoxantrone because of potential cardiac or carcinogenic effects. We prefer to use cyclophosphamide or mycophenolate mofetil in preference to methotrexate because evidence of efficacy is limited for this drug. We have less experience with azathioprine, but it may be an alternative for patients with limited options who are unable to tolerate conventional therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.